Irlanda - inglese - HPRA (Health Products Regulatory Authority)

amgen europe b.v. - filgrastim - solution for injection in pre-filled syringe - 30 mu (0.6) milligram(s)/millilitre - colony stimulating factors; filgrastim

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

amgen europe b.v. - filgrastim - solution for injection in pre-filled syringe - 48 mu (0.96) milligram(s)/millilitre - colony stimulating factors; filgrastim

Unione Europea - inglese - EMA (European Medicines Agency)

abz-pharma gmbh - filgrastim - neutropenia; hematopoietic stem cell transplantation; cancer - colony stimulating factors - biograstim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.biograstim is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.biograstim is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Unione Europea - inglese - EMA (European Medicines Agency)

ratiopharm gmbh - filgrastim - neutropenia; hematopoietic stem cell transplantation; cancer - immunostimulants, - filgrastim ratiopharm is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.filgrastim ratiopharm is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).in patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (anc) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of filgrastim ratiopharm is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.filgrastim ratiopharm is indicated for the treatment of persistent neutropenia (anc less than or equal to 1.0 x 109/l) in patients with advanced hiv infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Unione Europea - inglese - EMA (European Medicines Agency)

dompé biotec s.p.a. - pegfilgrastim - neutropenia; cancer - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Israele - inglese - Ministry of Health

amgen europe b.v. - pegfilgrastim - solution for injection - pegfilgrastim 10 mg/ml ml - pegfilgrastim - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. ( with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Singapore - inglese - HSA (Health Sciences Authority)

kyowa hakko kirin (singapore) pte. ltd. - filgrastim - injection, solution, concentrate - 30 mu/0.5 ml

Singapore - inglese - HSA (Health Sciences Authority)

kyowa hakko kirin (singapore) pte. ltd. - pegfilgrastim - injection, solution, concentrate - 6mg/0.6 ml

Singapore - inglese - HSA (Health Sciences Authority)

pfizer private limited - filgrastim - injection, solution - 0.120mg/0.2ml - filgrastim 0.120mg/0.2ml

Singapore - inglese - HSA (Health Sciences Authority)

pfizer private limited - filgrastim - infusion, solution - 0.300 mg/0.5ml - filgrastim 0.300 mg/0.5ml